NCT00107965View on ClinicalTrials.gov

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005

0.0025% PEP005 Topical Gel (Day 1,2 application)

DRUG

PEP005

0.01% PEP005 Topical Gel (Day 1,2 application)

DRUG

PEP005

0.05% PEP005 Topical Gel (Day 1,2 application)

DRUG

PEP005

Vehicle Gel (Day 1,2 application)

DRUG

PEP005

0.0025% PEP005 Topical Gel (Day 1,8 application)

DRUG

PEP005

0.01% PEP005 Topical Gel (Day 1,8 application)

DRUG

PEP005

0.05% PEP005 Topical Gel (Day 1,8 application)

DRUG

PEP005

Vehicle Gel (Day 1,8 application)

Trial Locations (6)

2050

Royal Prince Alfred Hospital, Sydney

3052

Skin and Cancer Foundation, Melbourne

3168

Monash Medical Centre, Melbourne

4000

Siller Medical, Brisbane

6160

Fremantle Dermatology, Fremantle

Private Dermaology Clinic, Fremantle

Sponsors

Lead Sponsor

Peplin
All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00107965 - Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses | Biotech Hunter | Biotech Hunter